Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 2690 participants.
Also called NCT04847232
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,690 participants
- Sponsor
- Registry
-
NCT04847232 -
2020-005561-14
-
- Other papers using this trial's data
- The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Brazil, Bulgaria, Canada, China, Czechia, Germany, Hungary, India, Italy, Japan, Malaysia, Mexico, Peru, Poland, Russia, Slovakia, Spain, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Terminated
Technical summary
Registry record NCT04847232. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-30 (actual); primary completion 2024-03-07 (actual). Results posted on 2025-06-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
- Condition
- Hyperkalemia
- Intervention (Drug)
- Sodium Zirconium Cyclosilicate (SZC)
- Intervention (Drug)
- SZC Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct04847232- Content hash
7ade58af97e5ab6d156f9c4913d756f01717fcdc377f22540b1bb236a8b0b57c